The Mayo Clinic Cancer Center (MCCC) oversees clinical trial conduct and participant safety of cancer clinical trials conducted at Mayo Clinic through the center's Data and Safety Monitoring (DSM) system. Data and safety monitoring is required for all types of clinical trials (pilot and phase l - lll ) . Monitoring of studies is proportionate to the risk associated with each study. Per NIH policy, a Data and Safety Monitoring Board (DSMB) is established for multi-site clinical trials involving interventions that entail potential risks to participants. The DSM system is in place and provides oversight of clinical research conducted through the MCCC. The process of oversight has been developed to ensure patient safety while promoting research with a high level of quality and integrity. The system is constructed in a manner that promotes ongoing review of each of the components. This permits timely changes in procedures and policies as the regulatory environment changes. It also provides a mechanism to identify internal areas of inconsistency, promoting modifications to the MCCC procedures to address these issues. DSM activities are accomplished through the center's Data and Safety Monitoring Board (DSMB) and Data and Safety Monitoring Committee (DSMC). The Data and Safety Monitoring Committee (DSMC) operates as a component of the DSM system and provides oversight related to the review of changes for investigator brochures, deviation reporting, and the review of adverse events across studies that require changes to the informed consent form. As opposed to the DSMB focus on elements of safety of individual trials, the DSMC is an added value service to investigators in that adverse events across studies for any given agent and investigator brochure (IB) changes that would mandate consent form or protocol procedure changes are identified and addressed to ensure consistency, standardization, and efficiencies. The Data and Safety Monitoring Board (DSMB) operates as a component of the DSM system and is structured to serve all pilot, phase I, II, and III interventional trials for which a DSMB does not exist and for which Mayo is the data center.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Bogenberger, James M; Delman, Devora; Hansen, Nanna et al. (2015) Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies. Leuk Lymphoma 56:226-9
Sami, Sarmed S; Ragunath, Krish; Iyer, Prasad G (2015) Screening for Barrett's esophagus and esophageal adenocarcinoma: rationale, recent progress, challenges, and future directions. Clin Gastroenterol Hepatol 13:623-34
Fackler, Mary Jo; Lopez Bujanda, Zoila; Umbricht, Christopher et al. (2014) Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res 74:2160-70
Porrata, Luis F; Ristow, Kay M; Habermann, Thomas M et al. (2014) Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma. Leuk Lymphoma 55:2728-38
Yoon, Harry H; Tougeron, David; Shi, Qian et al. (2014) KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). Clin Cancer Res 20:3033-43
Espejo, Rosario; Jeng, Yowjiun; Paulucci-Holthauzen, Adriana et al. (2014) PTP-PEST targets a novel tyrosine site in p120 catenin to control epithelial cell motility and Rho GTPase activity. J Cell Sci 127:497-508
Banck, Michaela S; Beutler, Andreas S (2014) Advances in small bowel neuroendocrine neoplasia. Curr Opin Gastroenterol 30:163-7
Boland, Jennifer M; Wampfler, Jason A; Jang, Jin S et al. (2014) Pulmonary adenocarcinoma with signet ring cell features: a comprehensive study from 3 distinct patient cohorts. Am J Surg Pathol 38:1681-8
Imperiale, Thomas F; Ransohoff, David F; Itzkowitz, Steven H et al. (2014) Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 370:1287-97

Showing the most recent 10 out of 340 publications